118 related articles for article (PubMed ID: 10587113)
1. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability.
Morales AA; Núñez-Gandolff G; Pérez NP; Véliz BC; Caballero-Torres I; Ducongé J; Fernández E; Crespo FZ; Veloso A; Iznaga-Escobar N
Nucl Med Biol; 1999 Aug; 26(6):717-23. PubMed ID: 10587113
[TBL] [Abstract][Full Text] [Related]
2. [Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF].
Calderón Sánchez O; Zayas Crespo F; Leyva Montaña R; Beckford Vera D; Gómez JA
Rev Esp Med Nucl; 2005; 24(1):38-44. PubMed ID: 15701345
[TBL] [Abstract][Full Text] [Related]
3. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies.
Morales AA; Ducongé J; Alvarez-Ruiz D; Becquer-Viart ML; Núñez-Gandolff G; Fernández E; Caballero-Torres I; Iznaga-Escobar N
Nucl Med Biol; 2000 Feb; 27(2):199-206. PubMed ID: 10773550
[TBL] [Abstract][Full Text] [Related]
4. Preparation and comparative evaluation of 99mTc-labeled 2-iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies.
Mishra AK; Iznaga-Escobar N; Figueredo R; Jain VK; Dwarakanath BS; Pérez-Rodríguez R; Sharma RK; Mathew TL
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):653-60. PubMed ID: 12616957
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3.
Morales AA; Crespo FZ; Gandolff GN; Iznaga Escobar N; Pérez NP; Hernández JC
Nucl Med Biol; 1998 Jan; 25(1):25-30. PubMed ID: 9466358
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
[TBL] [Abstract][Full Text] [Related]
9. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
[TBL] [Abstract][Full Text] [Related]
12. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
Mishra G; Panwar P; Mishra AK
Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
[TBL] [Abstract][Full Text] [Related]
14. A freeze dried kit formulation for the preparation of 99mTc-EHDP-MoAb-IOR CEA1 complex.
Ferro-Flores G; Lezama-Carrasco J
Nucl Med Biol; 1994 Oct; 21(7):1013-6. PubMed ID: 9234358
[TBL] [Abstract][Full Text] [Related]
15. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
Ducongé J; Fernández-Sánchez E; Alvarez D
Biopharm Drug Dispos; 2004 May; 25(4):177-86. PubMed ID: 15108220
[TBL] [Abstract][Full Text] [Related]
16. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
17. [Radiolabeling of a new agent for the study of colorectal tumors].
Quesada Cepero W; Pimentel González G; Oliva González J; Pérez Tenorio G; Aguiar Cabeza E; Sánchez Monzón I; Hernández Romero O; Rebustillo Sierra M
Rev Esp Med Nucl; 1998; 17(2):82-8. PubMed ID: 9611277
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m labelling of the IOR CEA 1 monoclonal antibody: evaluation of different methods.
Gano L; Fernandes C; Cantinho G; Santos AI; Pena H; Vieira R; Salgado L; Patrício L
Nuklearmedizin; 1997 Sep; 36(6):205-12. PubMed ID: 9380538
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
